CORDIS
EU research results

CORDIS

English EN

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as drugs against tuberculosis (NEW ANTIMYCOBACTERIALS)

Project information

Grant agreement ID: QLK2-CT-2002-00887

  • Start date

    1 September 2002

  • End date

    31 August 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 081 192

  • EU contribution

    € 1 500 000

Coordinated by:

PHILIPPS UNIVERSITY MARBURG

Germany

Objective

A new drug against tuberculosis (TB) will be developed based on the inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. The DOXP pathway supplies M. tuberculosis with essential isoprenoids. In mammals, the DOXP pathway is absent and isoprenoids are synthesised by the evaluate pathway. Therefore, inhibitors of the DOXP pathway are non-toxic for the human host. Inhibitors of DOXPreductoisomerase (Dry), key enzymes of the DOXP pathway, are to be developed as potential anti-TB drugs. In addition, the crystal structure of the Gape enzyme will be solved to provide the base for future drug development.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

PHILIPPS UNIVERSITY MARBURG

Address

Marbacher Weg 6
35032 Marburg

Germany

Participants (7)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE

Netherlands

GENT UNIVERSITY

Belgium

JUSTUS-LIEBIG-UNIVERSITY OF GIESSEN

Germany

QUEEN MARY AND WESTFIELD COLLEGE - UNIVERSITY OF LONDON

United Kingdom

UNIVERSITE LOUIS PASTEUR, STRASBOURG 1

France

UNIVERSITE PAUL SABATIER DE TOULOUSE III

France

Project information

Grant agreement ID: QLK2-CT-2002-00887

  • Start date

    1 September 2002

  • End date

    31 August 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 2 081 192

  • EU contribution

    € 1 500 000

Coordinated by:

PHILIPPS UNIVERSITY MARBURG

Germany